These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26141614)

  • 1. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.
    Fourier A; Portelius E; Zetterberg H; Blennow K; Quadrio I; Perret-Liaudet A
    Clin Chim Acta; 2015 Sep; 449():9-15. PubMed ID: 26141614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes.
    Perret-Liaudet A; Pelpel M; Tholance Y; Dumont B; Vanderstichele H; Zorzi W; Elmoualij B; Schraen S; Moreaud O; Gabelle A; Thouvenot E; Thomas-Anterion C; Touchon J; Krolak-Salmon P; Kovacs GG; Coudreuse A; Quadrio I; Lehmann S
    J Alzheimers Dis; 2012; 31(1):13-20. PubMed ID: 22495345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.
    Hansson O; Batrla R; Brix B; Carrillo MC; Corradini V; Edelmayer RM; Esquivel RN; Hall C; Lawson J; Bastard NL; Molinuevo JL; Nisenbaum LK; Rutz S; Salamone SJ; Teunissen CE; Traynham C; Umek RM; Vanderstichele H; Vandijck M; Wahl S; Weber CJ; Zetterberg H; Blennow K
    Alzheimers Dement; 2021 Sep; 17(9):1575-1582. PubMed ID: 33788410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
    Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
    Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.
    Mattsson N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2010 May; 48(5):603-7. PubMed ID: 20201744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International quality control survey of neurochemical dementia diagnostics.
    Lewczuk P; Beck G; Ganslandt O; Esselmann H; Deisenhammer F; Regeniter A; Petereit HF; Tumani H; Gerritzen A; Oschmann P; Schröder J; Schönknecht P; Zimmermann K; Hampel H; Bürger K; Otto M; Haustein S; Herzog K; Dannenberg R; Wurster U; Bibl M; Maler JM; Reubach U; Kornhuber J; Wiltfang J
    Neurosci Lett; 2006 Nov; 409(1):1-4. PubMed ID: 17045397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.
    Bjerke M; Engelborghs S
    J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment.
    Parnetti L; Eusebi P
    J Alzheimers Dis; 2018; 64(s1):S281-S287. PubMed ID: 29562517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.
    Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A
    J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
    Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
    Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.